Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Asian Stocks Drop as Trump Signals Iran War Escalation 
South Korea Manufacturing PMI Hits 4-Year High in March 2025 Driven by Semiconductor Demand 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Trump Expands Tariffs on Pharmaceuticals and Metals One Year After Liberation Day 
South Korea's Inflation Rises Modestly in March Amid Oil Price Pressures 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Oil Prices Slide as Iran Tensions Ease and U.S. Crude Stockpiles Swell 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Gold Prices Drop as Trump Escalates Iran Threats, Oil Surges 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Japan's Business Confidence Rises Despite Iran War Uncertainty, BOJ Rate Hike Expected 
Japan's Services Sector Growth Slows in March Amid Rising Middle East Tensions 
Oil Prices Climb as Middle East Conflict Keeps Supply Risks Elevated 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Cresco Labs Inc. and Columbia Care are cannabis and medical marijuana companies that have previously announced their merger through an acquisition deal. In March 2022, they agreed to a transaction that would have created the largest cannabis operator in the United States, but the agreement seems to have gone up in smoke.
Cresco Labs and Columbia made a new announcement on Monday, July 31, stating they have terminated their $2 billion merger deal. This development comes as the industry is waiting for banking reforms, as per CNBC.
Moreover, it was suggested that the contract has been called off as the cannabis industry has been showing indications of a slowdown as it also deals with various economic issues and challenges with regulators. The cannabis companies mutually agreed to scrap their agreement, so there will be no penalties or fees to pay for both parties.
Another reason for the failure of the merger is the fact that Cresco Labs and Columbia Care were not able to unload enough assets required to secure the regulators' seal of approval. They were given the June 30 deadline for this but failed to comply.
"In light of the evolving landscape in the cannabis industry, we believe the decision to terminate the planned transaction is in the long-term interest of Cresco Labs and our shareholders," Cresco Labs' co-founder and chief executive officer, Charles Bachtell, said in a press release.
"We want to express our sincere gratitude to Columbia Care for their valuable collaboration and dedication during this transaction. While this is not the outcome we originally hoped for, we are confident Cresco Labs is in a stronger position moving forward."
Columbia Care's co-founder and CEO, Nicholas Vita, added, "After careful consideration, we are confident in the mutual decision to move forward as separate, standalone companies. This is the best path forward for Columbia Care's employees, customers, and shareholders. We are thankful for the collaboration and partnership with the Cresco team throughout this extensive process."
Photo by: Kimzy Nanney/Unsplash
